Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to United Therapeutics Corporation (NASDAQ: UTHR) filings with the U.S. Securities and Exchange Commission, along with AI-generated summaries to help interpret key disclosures. United Therapeutics is a biotechnology and pharmaceutical company whose common stock trades on the Nasdaq Global Select Market, as noted in its Form 8-K reports. The company develops therapies for pulmonary arterial hypertension and related lung diseases and pursues technologies to expand the availability of transplantable organs as part of its public benefit corporation mandate.
In these SEC filings, investors can review current reports on Form 8-K that describe material events such as quarterly earnings releases, clinical milestones, share repurchase arrangements, and shareholder meeting outcomes. For example, United Therapeutics has filed 8-Ks to furnish press releases on quarterly financial results, to report positive TETON-2 clinical data for nebulized Tyvaso in idiopathic pulmonary fibrosis, and to disclose accelerated share repurchase agreements under a board-authorized share repurchase program.
Filings also document corporate governance and compensation matters, including amendments and restatements of the company’s stock incentive plan, vote results from the annual meeting of shareholders, and the listing of common stock on the Nasdaq Global Select Market under the symbol UTHR. These documents provide insight into equity compensation structures, director elections, advisory votes on executive pay, and auditor ratification.
Through this page, you can quickly locate United Therapeutics’ 8-Ks and, where available, other forms such as 10-K annual reports, 10-Q quarterly reports, and Forms 3, 4, and 5 related to insider ownership and transactions. AI-powered summaries highlight the main points of lengthy filings, explain complex sections in simpler language, and draw attention to items that often matter to investors, such as revenue drivers, capital return actions, and significant clinical or regulatory updates. Real-time updates from EDGAR ensure that new UTHR filings appear promptly, helping users monitor the company’s regulatory and disclosure record in one place.
United Therapeutics Corp director Ray Kurzweil reported a set of transactions involving company stock. On March 4, 2026, he exercised a stock option for 4,910 shares, which resulted in acquiring 4,910 shares of common stock at a stated price per share of
UNITED THERAPEUTICS Corp director Tommy G Thompson reported multiple transactions on
On the same date, he acquired 2,000 shares of common stock through this option exercise at a price of
A footnote states that his direct holdings include 880 additional common shares to be issued on or about
UNITED THERAPEUTICS Corp director Christopher Causey exercised stock options for 20 shares on March 4, 2026, converting them into common stock at a price of $119.76 per share. He then sold 20 common shares in an open-market transaction at a weighted average price of $490.1685 per share.
The option exercise and subsequent sale were carried out under a pre-arranged Rule 10b5-1 trading plan that Causey entered into on September 30, 2025. The sale occurred in multiple trades, with individual prices ranging from $490.12 to $490.21, and left him with 4,190 common shares held directly.
United Therapeutics Chairperson and CEO Martine Rothblatt reported a mix of option exercises and stock sales. On March 3, 2026, she exercised 9,500 stock options, receiving an equal number of common shares, then sold 9,500 common shares in multiple open-market transactions.
These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. After the reported sales, she directly held 130 common shares, in addition to indirect holdings through her spouse and family trusts.
Morgan Stanley Smith Barney LLC files Form 144 to sell common shares of UTHR via stock option exercises. The notice lists multiple proposed sales dated
United Therapeutics Corporation submitted a Form 144 notice of proposed sale of securities by an insider. The filing lists a planned stock option exercise and proposed sale of 20 common shares on
United Therapeutics reported a Form 144 notice proposing the sale of 2,000 common shares. The filing lists the proposed sale date as
United Therapeutics Corp director Jan Malcolm reported an open-market sale of 50 shares of common stock on March 3, 2026 at a price of
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported a series of insider trades in the company’s common stock. On March 2, 2026, she exercised 9,500 stock options at an exercise price of
That same day, she conducted multiple open‑market sales totaling 9,500 shares of common stock, at reported weighted‑average prices generally between about
The filing also reports indirect holdings of common stock through a spouse and various family trusts, where the reporting person or her immediate family share or hold investment power and are beneficiaries.